Teva Announces Appointment of New Chief Financial Officer
2019年11月7日 - 9:05PM
ビジネスワイヤ(英語)
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)
announced today the appointment of Eli Kalif as Executive Vice
President and Chief Financial Officer. Mr. Kalif will begin his
employment on December 22, 2019. He will be based out of Teva’s
global headquarters in Israel.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20191107005406/en/
Eli Kalif, appointed CFO of Teva
Pharmaceutical Industries (Photo: Business Wire)
Mr. Kalif joins Teva with broad experience in corporate and
operational finance, most recently as Senior Vice President,
Finance, leading the finance organization that supports the Global
Operations, Components & services business at Flex Ltd.
(NASDAQ: FLEX), a global technology design and manufacturing
service provider with extensive operations that include 85
production sites in 30 countries.
"Eli brings to Teva more than 20 years of leadership roles with
a proven track record in complex financial organizations, where he
was responsible for leading global teams supporting
multi-billion-dollar operations within a dynamic market
environment," said Kåre Schultz, Teva's President and CEO. "He
possesses a profound understanding of global production structures
and has experience in leading organizational transformation, as
well as building world class financial organizations. With deep
functional expertise and technical knowledge in all aspects of
corporate finance, financial planning and accounting, I believe Eli
has the required leadership capabilities to strategically manage
our debt, enabling the company to move forward from the
restructuring phase to optimizing Teva for success and future
sustainable growth."
Mr. Kalif stated, "I look forward to joining Teva's leadership
team and leading its finance organization to contribute to Teva's
future success as the company progresses to the next phase of its
strategy."
Kåre Schultz, Teva’s President and CEO, will perform the
functions of the Company’s chief financial officer from the date of
Mr. McClellan’s departure on November 8, 2019 until Mr. Kalif
begins employment with the Company on December 22, 2019.
Eli Kalif bio
Eli Kalif has held senior positions at Flex Ltd, a US-based
global technology design and manufacturing service provider, with
annual revenues of approximately $25 billion. His most recent
position was Senior Vice President Finance Global Operations,
Components & Services, which he has held since 2013, and he
previously served as Vice President of Finance for the Americas as
well as in Europe & South America.
Mr. Kalif is a Certified Public Accountant (CPA) with a degree
in Accounting and Economics.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people’s lives
for more than a century. We are a global leader in generic and
specialty medicines with a portfolio consisting of over 3,500
products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day, and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of specialty and biopharmaceutical
products. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, which are based on management’s current beliefs and
expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future
results, performance or achievements to differ significantly from
that expressed or implied by such forward-looking statements.
Important factors that could cause or contribute to such
differences include risks relating to our ability to successfully
execute a smooth transition of CFO functions as well as our ability
to retain and recruit qualified executives; uncertainties related
to, and failure to achieve, the potential benefits and success of
our senior management team and organizational structure; our
ability to successfully compete in the marketplace; our substantial
indebtedness, which may limit our ability to incur additional
indebtedness, engage in additional transactions or make new
investments; compliance, regulatory and litigation matters; other
financial and economic risks; and other factors discussed in our
Quarterly Reports on Form 10-Q for the first, second and third
quarters of 2019 and in our Annual Report on Form 10-K for the year
ended December 31, 2018, including in the sections captioned "Risk
Factors” and “Forward Looking Statements.” Forward-looking
statements speak only as of the date on which they are made, and we
assume no obligation to update or revise any forward-looking
statements or other information contained herein, whether as a
result of new information, future events or otherwise. You are
cautioned not to put undue reliance on these forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191107005406/en/
IR Contacts United States Kevin C. Mannix (215)
591-8912 Ran Meir 972 (3) 926-7516
PR Contacts United States Kelley Dougherty (973)
832-2810 Israel Yonatan Beker 972 (54) 888 5898
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 6 2024 まで 7 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 7 2023 まで 7 2024